# BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

> **NCT01034631** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hoosier Cancer Research Network** · enrollment: 154 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Everolimus
- **DRUG:** BNC105P

## Key facts

- **NCT ID:** NCT01034631
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2022-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01034631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01034631, "BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01034631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*